The PI3K family is on industry's ca ncer radarbecauseof the role of these kinases in cell growth, proliferation and differentiation. A decade ago, human genetics studies pointed to an opportunity for PI3K inhibitors in rare immunodeficiency disorders as well. In 2013, researchers reported in5cf'...
日前,FDA肿瘤药物咨询委员会(ODAC)关上了抗肿瘤药物PI3K抑制剂通过单臂试验上市批准的大门,并且建议此类药物需用随机对照数据来支持。单臂试验一度做为PI3K抑制剂药物获批上市的捷径,但FDA此次的态度却发生了反转。 因为此前没有对抗肿瘤药物PI3K抑制剂的疗效剂量毒性关系进行仔细评估,所以FDA建议使用随机对照临床试验来...
Inavolisibis a phosphatidylinositol 3-kinase (PI3K)-inhibitor, primarily PI3K-alpha, that degrades mutated PI3K catalytic alpha subunit p110-alpha (encoded by PIK3CA gene) resulting in AKT phosphorylation inhibition. It is indicated in combination with palbociclib and fulvestrant for endocrine-resistant,...
immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021”的综述文章,详细综述了120种实体肿瘤治疗药物的性质,总结了其抗肿瘤活性的主要生物学机制,并分析了这些药物的靶点分布。作者
作用机制:磷脂酰肌醇-3-激酶(PI3K)抑制剂,主要抑制恶性B细胞中表达的PI3K-α和PI3K-δ 剂型与规格:粉针剂,每瓶60 mg。 不良反应:高血糖,腹泻,体力下降,高血压,白细胞减少,中性粒细胞减少症,恶心,下呼吸道感染,血小板减少症。 合成路线:见图15[19]。
The PI3K inhibitors exhibit a narrow range between an effective and toxic dose. Across the class, there has been limited dose exploration.” "For each approved PI3K inhibitor, there are exposure response relationships for safety, primarily for PI3K-associated toxicities. Conversely, e...
2022年10月8日,杭州医学院的姜少杰等人,在知名肿瘤学期刊Journal of Hematology & Oncology发表了题为“Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021”的综述文章,详细综述了120种实体肿瘤治疗药物的性质,总结了其抗肿...
2022年10月8日,杭州医学院的姜少杰等人,在知名肿瘤学期刊Journal of Hematology & Oncology发表了题为“Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021”的综述文章,详细综述了120种实体肿瘤治疗药物的性质,总结了其抗肿...
然而,Trodelvy的临床益处高度依赖于Trop-2的表达,在低Trop-2表达亚组中很难得出明确的结论。 参考文献: [1] Small-molecule inhibitors, immunecheckpointinhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.Journal of Hematology & Oncology2022....
本文参考2022年发表在Journal of Hematology& Oncology的一篇药物综述文章《Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021》,介绍1991-2021年FDA批准的24种乳腺癌治疗新药(这是该文作者统计的,不一定涵盖全)。